NCT01019876View on ClinicalTrials.gov

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

September 7, 2021

Study Completion Date

September 7, 2021

Conditions

Bone Marrow FailureOsteopetrosisFanconi AnemiaSevere Combined Immunodeficiency

Interventions

DRUG

Fludarabine

DRUG

Cyclophosphamide

DRUG

Busulfan

DRUG

Alemtuzumab

DRUG

Rabbit Anti-thymocyte Globulin

DRUG

Horse Anti-thymocyte Globulin

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors

lead

Columbia University

OTHER

NCT01019876 - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases | Biotech Hunter | Biotech Hunter